|
Abstract Presentation
Unlike oncology and inflammatory disease, the treatment of neurological disorders has not yet greatly benefitted from the advent of therapeutic antibodies. In view of the high medical need for specific drugs to treat neurological disorders and the resulting large commercial opportunity, the pharma and biotech industry have made large investments to overcome the many hurdles related to the use of biologicals versus small molecules in this field. In particular, recent developments in antibody-based treatments for large indications like Alzheimer’s disease and pain have the potential to make a big impact on the industry. |
|
About the speaker
Before joining PanGenetics in 2006, Arnoud Dijkstra spent 14 years in the Swiss pharmaceutical and biotech industry. Having received his Ph.D. from the Department of Biophysical Chemistry, Groningen, he joined the Pharma Research Department of Hoffmann-La Roche in Basel in 1992, where he spent eight years and held several positions in research management. After that he switched to biotech and was involved in setting up the Basel branch of the start-up Morphochem AG, where he served as VP of Operations for three years. He then joined Actelion Pharmaceuticals where, serving as Director of Business Development, he combined responsibility for Search and Evaluation with a role in Actelion's Investor Relations. |
 |
